Bill Gates Prepares for ‘Pandemic X’ with ‘Needle-Free’ Vaxx
Dec 20, 2023 15:12:54 GMT -5
Post by schwartzie on Dec 20, 2023 15:12:54 GMT -5
Bill Gates Prepares for ‘Pandemic X’ with New ‘Needle-Free’ mRNA Vaccines
Frank Bergman
December 20, 2023 - 12:31 pm
Microsoft co-founder Bill Gates is pumping vast sums of cash into a new “needle-free” mRNA vaccine technology in preparation for the so-called “Pandemic X.”
The Bill & Melinda Gates Foundation is teaming up with the Coalition for Epidemic Preparedness Innovations (CEPI) for the project.
CEPI was also founded by Gates with a $460 million investment.
Gates and the CEPI are investing $1.2 million in a startup to create under-the-tongue vaccine “wafers.”
The wafer can be stored at any temperature and can be administered without the use of needles.
Critics question the reliability of the technology and the safety of the mRNA platform.
With funding from Gates’ organization, the CEPI is partnering with Jurata Thin Film Inc. to develop a wafer-like mRNA film.
The wafers are taken under the tongue for needle-free mRNA vaccine delivery.
The huge cash injections from Gates will give a massive boost to help Jurata develop its proprietary vaccine platform.
According to the announcement, the $1.2M funding is just to get the project off the ground with more funding likely at later stages.
The company says its new platform stabilizes mRNA-containing lipid nanoparticle vaccine technologies in a thin film.
Jurata claims the film is designed to be “thermostable,” meaning it can be produced and stored at room temperature.
It can also remain stable for three years, eliminating the need for energy-intensive cold storage required by current mRNA vaccines.
The film can be placed inside the cheek or under the tongue to deliver the vaccine.
It can also be rehydrated with an aqueous solution and taken nasally or through other means that don’t require passage through the digestive tract.
Jurata and CEPI tout the technology as key to getting vaccines to poor people across the world.
“If shown to be successful,” CEPI said in its press release, the technology will “help expand access to mRNA vaccines in underserved regions and advance the global response to future emerging infectious disease outbreaks.”
JOIN THE FIGHT - DONATE TO SLAY NEWS TODAY!
However, scientists who spoke to The Defender said that “success” seemed unlikely anytime soon.
They also said the technology could pose problems even beyond the serious known risks with existing mRNA transfection technology.
Brian Hooker, Ph.D., senior director of science and research at Children’s Health Defense (CHD), said:
“Vaccines require cold storage (mostly refrigeration) and mRNA vaccines are especially susceptible to heat damage during shipping and storage.
“A thermostable platform completely eliminates the need for refrigeration and would be a huge breakthrough in getting rid of ‘cold chain requirements’ in delivering vaccines to the developing world and would also constitute a big cost savings in deployment overall.
“But outside of the other obvious issues with mRNA vaccines, I would be worried that the mRNA wouldn’t be as thermostable as purported and this would induce sequence mutations and other damage to the genetic code.”
Jurata is a small biotech firm developing the wafers for vaccine delivery and other therapeutics.
Its founders also founded Bamboo Therapeutics, a gene therapy biotech company acquired in 2016 by Pfizer.
The acquisition deal was valued at $827 million.
Jurata is the fifth partner announced as part of CEPI’s January 2022 call for proposals for thermostable vaccine manufacturing innovations.
The company said more announcements are on the horizon.
Recently, organizations including the World Health Organization (WHO), Bill Gates’s Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation, among others, have touted the potential benefits of non-needle vaccine delivery technologies including microarray patches, pens, and now microfilms as “groundbreaking,” “game changers” and “the future of vaccination.”
They claim these technologies have the potential to make vaccines accessible to remote areas, particularly in the Global South, where infrastructure for the cold storage necessary for vaccines is lacking, especially for mRNA vaccines which require ultra-cold temperatures of -20 degrees Celsius to -80 C.
They also say these technologies can “help promote vaccine uptake in areas of vaccine hesitancy” and reduce the need for providers by making it possible for people to self-administer vaccines.
As Slay News previously reported, scientists have also developed a new form of vaccine dubbed an “Air Vax.”
A group of leading American scientists has unveiled a new “Air Vax” in October.
It uses airborne aerosols to deliver mRNA vaccines straight into people’s lungs.
The new system was developed by researchers at Yale University.
The scientists developed the “Air Vax” to combat vaccine hesitancy as the new method bypasses the need for injections as it can be pumped into the air and used to vaccinate large crowds of people at once via the air they are breathing.
The mRNA in “Air Vax” is encapsulated into polymer nanoparticles, according to reports.
Following a study on mice, the results led researchers to declare that this “new method of delivery could radically change the way people are vaccinated.”
Air Vax can get the job done without a needle and syringe, allowing for greater vaccine coverage.
Scientists say the method will help the government to deliver vaccines for Covid and other viruses to people in remote areas of the world.
It will also overcome low vaccination rates among those who don’t want to get the injections.
Under the terms of the agreement with CEPI, Jurata committed to ensuring vaccine supply for the Global South by producing a volume of vaccines “required to meet public health needs,” setting affordable prices for Global South countries, and potentially transferring the technology to Global South manufacturers.
Thermostable needle-free technologies are being widely promoted even though few clinical trials on any of these technologies have been completed and no such vaccine has yet been approved by regulators.
CHD Staff Scientist J. Jay Couey, Ph.D., told The Defender he thought the hype around such technologies is a “red herring” meant to make the public think any problems with these vaccines are technical questions of storage or delivery method — rather than the much more serious threat posed by mRNA transfection technologies themselves.
Despite the limited research, the Gates Foundation in November gave Micron Biomedical $23.6 million to fund the first mass production of needle-free vaccine technology.
The U.S. Centers for Disease Control and Prevention (CDC) also partnered with Micron in the hope of using the technology on the American public.
CEPI says it hopes to use its funding to drive the development of such vaccines.
“We’re really looking to see a step change in the way that some of these vaccines can be stored and delivered,” said Ingrid Kromann, CEPI’s acting director of Vaccine Manufacturing and Supply Chain in a press release on the funding opportunity.
CEPI describes itself as “an innovative global partnership between public, private, philanthropic, and civil society organizations.”
The organization was launched at the World Economic Forum’s (WEF) annual meeting in Davos in 2017.
During the meeting, CEPI promised WEF members that its technology would “shorten the response time to epidemics by creating vaccines that could be released quickly once an outbreak occurs.”
After Gates founded CEPI with a $460 million investment, the Wellcome Trust and the WEF have also funded the organization.
Explaining why he founded CEPI, Bill Gates said:
“Unfortunately, even though there is substantial risk for epidemics, there is not a natural market for vaccines.
“You have to get governments to create the right incentive structure.
“If you can predict what the pathogens are going to be and can get vaccines stockpiled, then that would be a very good response.”
Gates Foundation employees hold both voting and non-voting positions on CEPI’s board, as do WHO employees.
“CEPI is yet another ‘Controligarch’-backed initiative that seeks to undermine national sovereignty and individual autonomy under the guise of philanthropy and saving lives,” Seamus Bruner, author of “Controligarchs: Exposing the Billionaire Class, their Secret Deals, and the Globalist Plot to Dominate Your Life,” told The Defender.
“They do this by leveraging crises — real and manufactured — to transfer decision making away from elected representatives to so-called experts and supranational organizations like the World Health Organization which are funded and controlled by an unelected — and therefore unaccountable — elite,” Bruner said.
CEPI’s mission under its preparedness plan is to fund the development of “rapid response platforms to develop vaccines against ‘Disease X’.”
“Disease X” is the WHO’s placeholder name for a disease that is currently unknown or not in existence, but that has the potential to be devastating for humanity.
The specter of Disease X was part of the rationale for the World Health Assembly to increase the WHO’s budget by 20% in June.
CEPI argues “the faster an effective vaccine is developed and deployed, the faster a potential pandemic threat can be contained and controlled if it is used.”
“The endless regimen of drugs and gene therapies that CEPI is working on — delivered via injections and other mechanisms — may end up being voluntary,” Bruner said.
“But if Controligarchs like CEPI’s primary individual benefactor Bill Gates have their way, they will be mandatory.”
link
Frank Bergman
December 20, 2023 - 12:31 pm
Microsoft co-founder Bill Gates is pumping vast sums of cash into a new “needle-free” mRNA vaccine technology in preparation for the so-called “Pandemic X.”
The Bill & Melinda Gates Foundation is teaming up with the Coalition for Epidemic Preparedness Innovations (CEPI) for the project.
CEPI was also founded by Gates with a $460 million investment.
Gates and the CEPI are investing $1.2 million in a startup to create under-the-tongue vaccine “wafers.”
The wafer can be stored at any temperature and can be administered without the use of needles.
Critics question the reliability of the technology and the safety of the mRNA platform.
With funding from Gates’ organization, the CEPI is partnering with Jurata Thin Film Inc. to develop a wafer-like mRNA film.
The wafers are taken under the tongue for needle-free mRNA vaccine delivery.
The huge cash injections from Gates will give a massive boost to help Jurata develop its proprietary vaccine platform.
According to the announcement, the $1.2M funding is just to get the project off the ground with more funding likely at later stages.
The company says its new platform stabilizes mRNA-containing lipid nanoparticle vaccine technologies in a thin film.
Jurata claims the film is designed to be “thermostable,” meaning it can be produced and stored at room temperature.
It can also remain stable for three years, eliminating the need for energy-intensive cold storage required by current mRNA vaccines.
The film can be placed inside the cheek or under the tongue to deliver the vaccine.
It can also be rehydrated with an aqueous solution and taken nasally or through other means that don’t require passage through the digestive tract.
Jurata and CEPI tout the technology as key to getting vaccines to poor people across the world.
“If shown to be successful,” CEPI said in its press release, the technology will “help expand access to mRNA vaccines in underserved regions and advance the global response to future emerging infectious disease outbreaks.”
JOIN THE FIGHT - DONATE TO SLAY NEWS TODAY!
However, scientists who spoke to The Defender said that “success” seemed unlikely anytime soon.
They also said the technology could pose problems even beyond the serious known risks with existing mRNA transfection technology.
Brian Hooker, Ph.D., senior director of science and research at Children’s Health Defense (CHD), said:
“Vaccines require cold storage (mostly refrigeration) and mRNA vaccines are especially susceptible to heat damage during shipping and storage.
“A thermostable platform completely eliminates the need for refrigeration and would be a huge breakthrough in getting rid of ‘cold chain requirements’ in delivering vaccines to the developing world and would also constitute a big cost savings in deployment overall.
“But outside of the other obvious issues with mRNA vaccines, I would be worried that the mRNA wouldn’t be as thermostable as purported and this would induce sequence mutations and other damage to the genetic code.”
Jurata is a small biotech firm developing the wafers for vaccine delivery and other therapeutics.
Its founders also founded Bamboo Therapeutics, a gene therapy biotech company acquired in 2016 by Pfizer.
The acquisition deal was valued at $827 million.
Jurata is the fifth partner announced as part of CEPI’s January 2022 call for proposals for thermostable vaccine manufacturing innovations.
The company said more announcements are on the horizon.
Recently, organizations including the World Health Organization (WHO), Bill Gates’s Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation, among others, have touted the potential benefits of non-needle vaccine delivery technologies including microarray patches, pens, and now microfilms as “groundbreaking,” “game changers” and “the future of vaccination.”
They claim these technologies have the potential to make vaccines accessible to remote areas, particularly in the Global South, where infrastructure for the cold storage necessary for vaccines is lacking, especially for mRNA vaccines which require ultra-cold temperatures of -20 degrees Celsius to -80 C.
They also say these technologies can “help promote vaccine uptake in areas of vaccine hesitancy” and reduce the need for providers by making it possible for people to self-administer vaccines.
As Slay News previously reported, scientists have also developed a new form of vaccine dubbed an “Air Vax.”
A group of leading American scientists has unveiled a new “Air Vax” in October.
It uses airborne aerosols to deliver mRNA vaccines straight into people’s lungs.
The new system was developed by researchers at Yale University.
The scientists developed the “Air Vax” to combat vaccine hesitancy as the new method bypasses the need for injections as it can be pumped into the air and used to vaccinate large crowds of people at once via the air they are breathing.
The mRNA in “Air Vax” is encapsulated into polymer nanoparticles, according to reports.
Following a study on mice, the results led researchers to declare that this “new method of delivery could radically change the way people are vaccinated.”
Air Vax can get the job done without a needle and syringe, allowing for greater vaccine coverage.
Scientists say the method will help the government to deliver vaccines for Covid and other viruses to people in remote areas of the world.
It will also overcome low vaccination rates among those who don’t want to get the injections.
Under the terms of the agreement with CEPI, Jurata committed to ensuring vaccine supply for the Global South by producing a volume of vaccines “required to meet public health needs,” setting affordable prices for Global South countries, and potentially transferring the technology to Global South manufacturers.
Thermostable needle-free technologies are being widely promoted even though few clinical trials on any of these technologies have been completed and no such vaccine has yet been approved by regulators.
CHD Staff Scientist J. Jay Couey, Ph.D., told The Defender he thought the hype around such technologies is a “red herring” meant to make the public think any problems with these vaccines are technical questions of storage or delivery method — rather than the much more serious threat posed by mRNA transfection technologies themselves.
Despite the limited research, the Gates Foundation in November gave Micron Biomedical $23.6 million to fund the first mass production of needle-free vaccine technology.
The U.S. Centers for Disease Control and Prevention (CDC) also partnered with Micron in the hope of using the technology on the American public.
CEPI says it hopes to use its funding to drive the development of such vaccines.
“We’re really looking to see a step change in the way that some of these vaccines can be stored and delivered,” said Ingrid Kromann, CEPI’s acting director of Vaccine Manufacturing and Supply Chain in a press release on the funding opportunity.
CEPI describes itself as “an innovative global partnership between public, private, philanthropic, and civil society organizations.”
The organization was launched at the World Economic Forum’s (WEF) annual meeting in Davos in 2017.
During the meeting, CEPI promised WEF members that its technology would “shorten the response time to epidemics by creating vaccines that could be released quickly once an outbreak occurs.”
After Gates founded CEPI with a $460 million investment, the Wellcome Trust and the WEF have also funded the organization.
Explaining why he founded CEPI, Bill Gates said:
“Unfortunately, even though there is substantial risk for epidemics, there is not a natural market for vaccines.
“You have to get governments to create the right incentive structure.
“If you can predict what the pathogens are going to be and can get vaccines stockpiled, then that would be a very good response.”
Gates Foundation employees hold both voting and non-voting positions on CEPI’s board, as do WHO employees.
“CEPI is yet another ‘Controligarch’-backed initiative that seeks to undermine national sovereignty and individual autonomy under the guise of philanthropy and saving lives,” Seamus Bruner, author of “Controligarchs: Exposing the Billionaire Class, their Secret Deals, and the Globalist Plot to Dominate Your Life,” told The Defender.
“They do this by leveraging crises — real and manufactured — to transfer decision making away from elected representatives to so-called experts and supranational organizations like the World Health Organization which are funded and controlled by an unelected — and therefore unaccountable — elite,” Bruner said.
CEPI’s mission under its preparedness plan is to fund the development of “rapid response platforms to develop vaccines against ‘Disease X’.”
“Disease X” is the WHO’s placeholder name for a disease that is currently unknown or not in existence, but that has the potential to be devastating for humanity.
The specter of Disease X was part of the rationale for the World Health Assembly to increase the WHO’s budget by 20% in June.
CEPI argues “the faster an effective vaccine is developed and deployed, the faster a potential pandemic threat can be contained and controlled if it is used.”
“The endless regimen of drugs and gene therapies that CEPI is working on — delivered via injections and other mechanisms — may end up being voluntary,” Bruner said.
“But if Controligarchs like CEPI’s primary individual benefactor Bill Gates have their way, they will be mandatory.”
link
